New drug combo targets rare BRAF mutations in advanced cancers

NCT ID NCT03839342

Ongoing Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests two oral drugs, binimetinib and encorafenib, in 26 adults with advanced solid tumors that have specific non-V600E BRAF mutations and no standard treatment options. The main goal is to see if the combination shrinks tumors. Researchers will also monitor side effects and how long patients live without the cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: binimetinib and encorafenib
What this could lead to: If successful, this could provide a new treatment option for people with advanced solid tumors that have certain rare BRAF mutations and have run out of standard therapies.
What could go wrong: This is a small, early-phase study with only 26 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Princess Margaret Cancer Centre

Toronto, Ontario, M5G2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.